Leanne Lanieri

950 total citations
17 papers, 286 citations indexed

About

Leanne Lanieri is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Leanne Lanieri has authored 17 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Molecular Biology. Recurrent topics in Leanne Lanieri's work include HER2/EGFR in Cancer Research (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and CAR-T cell therapy research (3 papers). Leanne Lanieri is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and CAR-T cell therapy research (3 papers). Leanne Lanieri collaborates with scholars based in United States. Leanne Lanieri's co-authors include Jose F. Ponte, Jan Pinkas, Jennifer A. Coccia, Olga Ab, Laura M. Bartle, Yinghui Zhou, Rodrigo Ruiz‐Soto, Ravi Chari, Wayne C. Widdison and Thomas A. Keating and has published in prestigious journals such as Blood, Cancer Research and Bioconjugate Chemistry.

In The Last Decade

Leanne Lanieri

16 papers receiving 278 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leanne Lanieri United States 7 179 137 86 43 33 17 286
Diana P. English United States 14 232 1.3× 79 0.6× 140 1.6× 55 1.3× 49 1.5× 24 447
G. Rowlinson United Kingdom 7 122 0.7× 285 2.1× 94 1.1× 53 1.2× 46 1.4× 10 435
Veena S. John United States 7 142 0.8× 88 0.6× 102 1.2× 11 0.3× 58 1.8× 26 268
Mary Flanagan Quinn United States 6 173 1.0× 25 0.2× 284 3.3× 27 0.6× 42 1.3× 12 381
Joshua Donaldson United States 7 97 0.5× 102 0.7× 153 1.8× 24 0.6× 21 0.6× 11 263
Pengfei Jiang China 9 134 0.7× 103 0.8× 98 1.1× 22 0.5× 38 1.2× 23 333
Anna Shvartsur United States 5 194 1.1× 69 0.5× 124 1.4× 23 0.5× 31 0.9× 6 317
Josefa Chuh United States 7 263 1.5× 247 1.8× 138 1.6× 21 0.5× 54 1.6× 9 397
Karianne G. Fleten Norway 12 108 0.6× 38 0.3× 140 1.6× 29 0.7× 41 1.2× 21 334
Marianne Boivin Canada 6 119 0.7× 58 0.4× 274 3.2× 36 0.8× 127 3.8× 7 447

Countries citing papers authored by Leanne Lanieri

Since Specialization
Citations

This map shows the geographic impact of Leanne Lanieri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne Lanieri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne Lanieri more than expected).

Fields of papers citing papers by Leanne Lanieri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne Lanieri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne Lanieri. The network helps show where Leanne Lanieri may publish in the future.

Co-authorship network of co-authors of Leanne Lanieri

This figure shows the co-authorship network connecting the top 25 collaborators of Leanne Lanieri. A scholar is included among the top collaborators of Leanne Lanieri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leanne Lanieri. Leanne Lanieri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Wu, Chuanfeng, Selami Demirci, Rahul Palchaudhuri, et al.. (2023). The Impact of CD45-Antibody-Drug Conjugate Conditioning on Clonal Dynamics and Immune Tolerance Post HSPC Transplantation in Rhesus Macaques. Blood. 142(Supplement 1). 3419–3419. 1 indexed citations
2.
Saha, Asim, Sharon L. Hyzy, Nicholas C. Clark, et al.. (2022). A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice. Blood. 139(11). 1743–1759. 20 indexed citations
3.
Ponte, Jose F., Leanne Lanieri, Eshita Khera, et al.. (2020). Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy. Molecular Cancer Therapeutics. 20(1). 203–212. 29 indexed citations
4.
5.
Ab, Olga, Laura M. Bartle, Leanne Lanieri, et al.. (2020). Abstract 2890: IMGN151 - A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Research. 80(16_Supplement). 2890–2890. 10 indexed citations
6.
Archer, Katie E., Erin K. Maloney, Olga Ab, et al.. (2019). Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs). Bioorganic & Medicinal Chemistry Letters. 29(17). 2455–2458. 5 indexed citations
7.
Qiu, Qifeng, Jose F. Ponte, Leanne Lanieri, et al.. (2019). Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing. ACS Medicinal Chemistry Letters. 10(10). 1393–1399. 18 indexed citations
8.
9.
Hicks, Stuart W., Katharine C. Lai, L. Cristina Gavrilescu, et al.. (2017). The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia. 19(9). 661–671. 27 indexed citations
10.
Miller, Michael L., Jose F. Ponte, Leanne Lanieri, et al.. (2017). Abstract 53: Antibody-drug conjugates (ADCs) of peptide-linked Indolino-Benzodiazepine (IGN) DNA-alkylator provides improved anti-tumor activity over that of a crosslinker. Cancer Research. 77(13_Supplement). 53–53. 1 indexed citations
11.
Widdison, Wayne C., Jose F. Ponte, Leanne Lanieri, et al.. (2017). Abstract 2186: Peptide-cleavable maytansinoid (ADCs) induce high bystander killing leading to improved anti-tumor activity in vivo. Cancer Research. 77(13_Supplement). 2186–2186. 1 indexed citations
12.
13.
Ponte, Jose F., Xiuxia Sun, Nicholas C. Yoder, et al.. (2016). Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody–Maytansinoid Conjugates. Bioconjugate Chemistry. 27(7). 1588–1598. 65 indexed citations
14.
Deckert, Jutta, Callum M. Sloss, Katie O’Callaghan, et al.. (2015). IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models. Blood. 126(23). 1548–1548. 3 indexed citations
15.
Ponte, Jose F., et al.. (2015). Abstract C170: Preclinical evaluation of mirvetuximab soravtansine (IMGN853) combination therapy in ovarian cancer xenograft models. Molecular Cancer Therapeutics. 14(12_Supplement_2). C170–C170. 2 indexed citations
16.
Deckert, Jutta, Jose F. Ponte, Jennifer A. Coccia, et al.. (2014). Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC). Blood. 124(21). 3119–3119. 3 indexed citations
17.
Singh, Rajeeva, Nathan Fishkin, Yelena Kovtun, et al.. (2013). Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).. Molecular Cancer Therapeutics. 12(11_Supplement). C164–C164.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Diana P. English Breakdown of academic impact, for papers by G. Rowlinson Breakdown of academic impact, for papers by Veena S. John Breakdown of academic impact, for papers by Mary Flanagan Quinn Breakdown of academic impact, for papers by Joshua Donaldson Breakdown of academic impact, for papers by Pengfei Jiang Breakdown of academic impact, for papers by Anna Shvartsur Breakdown of academic impact, for papers by Josefa Chuh Breakdown of academic impact, for papers by Karianne G. Fleten Breakdown of academic impact, for papers by Marianne Boivin
Rankless by CCL
2026